A new study from the University of California San Diego School of Medicine (UC San Diego) has revealed that individuals diagnosed with cannabis use disorder (CUD) face over three times the risk of developing oral cancer within a five‑year period compared to people without the disorder.
Analyzing electronic health records from more than 45,000 patients—including 949 diagnosed with CUD—the researchers reported an adjusted odds ratio (OR) of approximately 3.25 (i.e. a 325 % increased risk), even after controlling for age, sex, body mass index and smoking status.
The risk is even more pronounced among patients who also smoke tobacco. Tobacco users with CUD experienced a 624 % higher likelihood of developing oral cancer relative to tobacco smokers without CUD.
These findings add to a growing body of evidence linking CUD with elevated risks for cancers of the oral and head‑neck region.
A large multicenter study published in JAMA Otolaryngology–Head & Neck Surgery last year found that individuals with cannabis use disorder had between 3.5 and 5 times higher risk of developing head and neck cancers—including oral, oropharyngeal, and laryngeal types—than those without the disorder.
The hypothesized mechanism stems in part from carcinogens in cannabis smoke, which is typically unfiltered and inhaled deeply, burning at higher temperatures than tobacco and causing inflammation and DNA damage in the mouth and throat tissues.
Cannabis smoke shares many combustion byproducts with tobacco, and these compounds damage the epithelial lining of the mouth and upper airway. Even when analyses exclude smoking status, the elevated cancer risk associated with CUD persists—suggesting that other factors, such as THC’s immunosuppressive effects, may play a role.
Moreover, observational data and systematic reviews reveal that long‑term cannabis smoking is linked to respiratory symptoms like chronic bronchitis, lung inflammation, and potentially to increased cancer risks in lungs and other organs—though earlier meta‑analyses had sometimes found inconclusive results due to methodological limitations.
With roughly 17.7 million people reporting daily or near‑daily cannabis use in 2022—and estimates suggesting up to 30 % of users may develop CUD—these findings have far-reaching importance.
As cannabis becomes more legally and socially accepted, there is a critical need to integrate these risks into public health messaging, clinical guidelines, and patient counseling.
Cancer screening protocols should consider including targeted oral examinations for individuals diagnosed with CUD.
Substance use treatment programs should integrate oral health education and screening support.
Healthcare practitioners must be aware of these associations and advise patients accordingly—especially those who both smoke tobacco and cannabis.
Experts emphasize that while the current data are compelling, more rigorous, long‑term studies are needed—particularly to distinguish effects of smoking versus other forms of consumption like edibles or vaporization.
The UC San Diego study relies on diagnostic codes, which may underreport both cannabis use and cancer cases—potentially underestimating the true risk.
The results are observational, not proving causation, and may be influenced by additional confounders such as alcohol use, diet, socio-economic status, HPV infection, or other lifestyle factors.
The newly published UC San Diego study adds a critical dimension to our understanding of cannabis use disorder’s health risks, documenting a more than three‑fold increase in oral cancer risk within five years—rising to over six‑fold among tobacco users. Combined with prior research linking CUD to elevated head and neck cancer rates, these results underscore the urgent need for enhanced public health awareness, preventive screening, and further rigorous study.
Read more:
